Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIMS The endoscopic sleeve gastroplasty (ESG) has been shown to be effective for inducing weight loss. The efficacy of liraglutide, a glucagon-like peptide-1 agonist, to augment weight loss after ESG is unknown. This study aims to evaluate the efficacy of ESG and liraglutide (ESG-L) compared with ESG alone. METHODS This was a retrospective study of prospectively collected data from patients undergoing ESG at 3 outpatient clinics in Brazil, between November 2017 and July 2018. Liraglutide was offered to all patients 5 months after ESG. Patients that opted to take liraglutide (ESG-L) were matched 1:1 to patients that declined it (ESG). Primary outcome was percent total body weight loss (%TBWL), and percent excess weight loss (%EWL) 7 months after initiation of liraglutide (12 months after ESG). Secondary outcome was change in percent body fat 12 months after ESG. ESG technique and postprocedure follow-up was identical at all 3 sites. RESULTS Propensity score matching yielded 26 matched pairs. Adjusted comparisons between the 2 groups showed that patients who opted to take liraglutide had a superior mean %TBWL 7 months after initiation of liraglutide (ESG-L) compared with those that declined it (ESG), 24.72 ± 2.12% versus 20.51 ± 1.68% (p <0.001). ESG-L had a statistically greater reduction in percent body fat compared with ESG, 7.85 ± 1.26 versus 10.54 ± 1.88 (p <0.001) at 12 months. CONCLUSION Addition of liraglutide at 5 months results in superior weight loss and improved efficacy as demonstrated by decreased body fat 12 months after the ESG. Further studies are imperative to determine optimal dose, timing, and duration of liraglutide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Sjöström, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12012 · Cited by 1,835
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Cited by
Contemporary medical, device, and surgical therapies for obesity in adults
Perdomo, C. M., Cohen, R. V., Sumithran, P., Clément, K., & Frühbeck, G. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02403-5 · Cited by 738
Abad, J., Llop, E., Arias-Loste, M. T., Burgos-Santamaría, D., Martínez Porras, J. L., Iruzubieta, P., Graus, J., Ruiz-Antorán, B., Sánchez Yuste, M. R., Romero-Gómez, M., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.10.027 · Cited by 35
Vosburg, R. W., El Chaar, M., El Djouzi, S., Docimo, S., Choi, D., LaMasters, T., Srivastava, G., Shukla, A. P., Oviedo, R. J., Fitch, A., et al. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.07.002 · Cited by 24
AlKhatry, M., Rapaka, B., Maselli, D. B., Abboud, D. M., Brunaldi, V. O., Mahmoud, T., Ghazi, R., Abdul Razzak, F., Gala, K., Joudah, I., et al. (2023) · Endoscopy · doi:10.1055/a-2117-6274 · Cited by 23
“Thus, future management can combine this procedure with small-intestinal endoscopic bariatric and metabolic therapies and or metabolically active pharmacotherapies, such as glucagon-like peptide 1 receptor agonists in tandem or in sequence as a chronic disease management paradigm for NAFLD [17].”
BackgroundUpdates in endoscopic bariatric and metabolic therapies.
Qureshi, H., Saeed, N., & Jovani, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031126 · Cited by 21
“Patients who received the additional medical therapy had a higher mean %TBWL at 7 months after initiation of lirag-lutide compared with those who declined it (24.7% vs. 20.51; p < 0.001), as well as greater reduction in percent body fat (7.85% vs. 10.54%; p < 0.001) at 12 months [39].”
BackgroundInfluential
Metadata
- Authors
- Badurdeen, D., Hoff, A. C., Hedjoudje, A., Adam, A., Itani, M. I., Farha, J., Abbarh, S., Kalloo, A. N., Khashab, M. A., Singh, V. K., Oberbach, A., Neto, M. G., Barrichello, S., & Kumbhari, V.
- Venue
- Gastrointestinal Endoscopy
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 93
- Issue
- 6
- Pages
- 1316-1324.e1
- ISSN
- 0016-5107 (ISSN-L)
- OpenAlex
- W3092665842
- Cited by
- 72
- References
- 18
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss. https://app.cochat.ai/papers/10.1016/j.gie.2020.10.016
- The paper
- Badurdeen, D., Hoff, A. C., Hedjoudje, A., Adam, A., Itani, M. I., Farha, J., Abbarh, S., Kalloo, A. N., Khashab, M. A., Singh, V. K., Oberbach, A., Neto, M. G., Barrichello, S., & Kumbhari, V. (2021). Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss. Gastrointestinal Endoscopy. https://doi.org/10.1016/j.gie.2020.10.016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.